市場調査レポート

商品コード

1722973

バイオリアクターの市場規模、シェア、動向、予測：タイプ、用途、スケール、制御タイプ、地域別、2025年～2033年

Bioreactors Market Size, Share, Trends, and Forecast by Type, Usage, Scale, Control Type, and Region, 2025-2033

出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 434,585円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcelの印刷は一度のみ可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (5 User License)

USD 3,999 579,495円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcelの印刷は可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 724,405円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等の編集は可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.91円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

バイオリアクターの世界市場規模は2024年に80億米ドルとなりました。今後、IMARC Groupは、同市場が2033年までに196億米ドルに達し、2025年から2033年にかけて10.4%のCAGRを示すと予測しています。現在、北米が市場を独占しており、2024年には39.1%を超える大きな市場シェアを占めています。予防ワクチンのニーズの高まりとともに、効果的な治療薬の採用が増加していることが、主にバイオリアクターの市場シェアを押し上げています。

世界のバイオリアクターの市場は、モノクローナル抗体やワクチンなどの生物製剤に対する需要の高まりによって成長を遂げています。この背景には、バイオ医薬品製造の進歩があります。これとともに、汚染リスクと運用コストの削減で知られるシングルユースの採用が増加していることも、市場の成長をさらに加速させています。細胞・遺伝子治療研究の急速な進展や個別化医療への関心の高まりも需要を後押ししています。これとは別に、生物製剤製造に対する政府の支援やバイオシミラー製造に対する有利な規制も市場拡大に寄与しています。さらに、自動化および制御システムの技術的改良がバイオリアクターの性能を向上させ、バイオテクノロジーおよび製薬業界のニーズに対応し、市場を活性化しています。

米国は、バイオシミラー製造への注目の高まりに牽引され、主要市場として際立っています。この背景には、主要な生物製剤の特許切れと、代替品の低価格化があります。さらに、慢性疾患の蔓延がバイオ医薬品への投資を促し、スケーラブルで効率的なバイオリアクターシステムの必要性を煽っています。CDCの2024年調査報告書によると、米国では1億2,900万人が、心臓病、がん、糖尿病、肥満、高血圧など、米国保健福祉省が定義した主要な慢性疾患を少なくとも1つ持っており、42％が2つ以上、12％が5つ以上持っています。慢性疾患は、死亡原因のトップ10のうち5つを占めています。その有病率は20年以上にわたって着実に増加しており、今後もさらに増加すると予想されています。これに加え、幹細胞研究や組織工学などのバイオプロセス応用の拡大が、専門的なバイオリアクターに対する大きな需要を生み出しています。同時に、学術機関とバイオテクノロジー企業とのコラボレーションにより、バイオ製造技術の進歩が加速しています。さらに、食品および農業バイオテクノロジーにおけるバイオリアクターの役割の増大は、バイオリアクターの市場の見通しを明るいものにしています。

バイオリアクターの市場の動向：

シングルユースバイオリアクターの使用状況

シングルユースバイオリアクター（SUB）は、柔軟性、費用対効果、汚染リスクの低減などの利点により、幅広い人気を集めています。これが逆に市場を刺激しています。IMARCによると、世界のシングルユースバイオリアクターの市場規模は2023年に34億米ドルに達しました。今後、IMARC Groupは、2032年までに同市場が111億米ドルに達し、2024～2032年の成長率（CAGR）は13.8％に達すると予測しています。さらに、従来のステンレス製バイオリアクターとは異なり、SUBは使い捨てバッグを採用しており、バッチ間の大規模な洗浄や滅菌の必要性を排除するのに役立っています。2023年12月、セレクサスは、細胞の迅速な増殖のために最適な通気性を提供するエアリフト使い捨てバイオリアクターシステムを発表しました。この穏やかな撹拌方法は、通常、微生物発酵や細胞培養に適しています。これ以外にも、主要メーカーは革新的なSUB設計を製造しており、小規模調査から大規模生産ニーズまで対応しており、これがバイオリアクター市場の展望を後押ししています。例えば、2024年2月、開発・製造受託機関（CDMO）のWuXi Biologics社は、アイルランドに約3億4,000万米ドルを投資し、約5万4,000リットルの使い捨てバイオリアクター容量を持つシングルユースサイトを建設すると発表しました。さらに、2024年3月、サーモフィッシャーサイエンティフィック（TM）は、HyPerforma（TM）シングルユース・バイオリアクター（SUB）製品プラットフォームのアプリケーションに特化した一連の機能強化を発表しました。同様に、2024年3月にはDistek, Inc.が哺乳類細胞増殖と組換えタンパク質生産用のシングルユース・バイオリアクター（SUB）システムを発表しました。さらに、著名企業間の継続的な提携は、今後数年間で市場を拡大すると予測されています。例えば、2024年6月、Aragen Bioscience社とGetinge社は、後者のシングルユース生産リアクター（SUPR）の検証に成功したと発表しました。これに伴い、この提携はGetinge社の革新的なシングルユース技術とAragen社のバイオ医薬品製造に関する専門知識を組み合わせたものです。

オートメーションの進歩

重要なバイオリアクターの市場動向の一つは、自動化の継続的進歩です。新しい制御システムとバイオリアクターによる自動化の広範な統合は、pH、温度、溶存酸素などの重要なパラメータの正確な制御とリアルタイムのモニタリングを可能にし、バイオプロセスに革命をもたらしています。これは大きな成長促進要因として作用しています。例えば、2023年8月、Repligen CorporationとSartoriusは、統合されたプロセス分析技術（PAT）と事前に定義された高度な制御レシピを提供する完全互換の組込み型XCell ATFソフトウェアとハードウェアモジュールで構成される統合バイオリアクターシステムを発表しました。ガートナーによると、GenAIを含むAI主導の自動化が業務効率と敏捷性を高めるため、2023年の10％から2026年までに30％の企業がネットワーク活動の半分以上を自動化するといいます。これらの進歩はバイオリアクターのにますます適用され、データ駆動型の意思決定とプロセスの最適化を強化します。さらに、このシステムは、別個の細胞保持コントロールタワーを利用することなく、灌流プロセスにおける細胞増殖のコントロールと細胞保持を強化する合理的な方法をユーザーに提供することを目指しています。このほか、バイオテクノロジー・ソリューションのイノベーターの1つであるオートメイテッド・コントロール・コンセプツ（ACC）は、2023年9月、最先端のバイオリアクター制御・データプラットフォームであるLab Owlを発表しました。このプラットフォームは、複数のプロセスパラメーターの調整と正確なモニタリングを可能にし、一貫した再現性のある結果をもたらします。これとは別に、カルトザイムは2023年12月、AI、ハードウェア、クラウドコンピューティングを搭載したバイオリアクター・インテリジェント・オペレーション・ナノテクノロジー（BION）システムを発表し、バイオ製造プロセスを制御し、より効率的かつ最小限のコストで一貫した成果を達成します。さらに、実験室規模から生産規模へのシームレスなスケールアップを促進し、多数のバイオリアクターサイズで一貫した性能を確保するのに役立つため、高度な制御システムへの需要が高まっていることも、バイオリアクターの市場の収益を増加させています。例えば、2024年4月、カルチュア・バイオサイエンシズは、チャイニーズハムスター卵巣（CHO）細胞に対応するように設計された高度な制御システムとリアルタイムモニタリング機能を備えたバイオリアクターのを開発しました。

持続可能なバイオプロセスの開発

持続可能性は、市場において重要な検討事項となりつつあります。有力企業はエネルギー消費と廃棄物発生を最小限に抑えることに注力しており、これがバイオリアクターの市場の成長を刺激しています。2023年10月、奈良先端科学技術大学院大学と藤田大学の研究チームは、コンピューターによるフィードフォワード制御と遺伝子組み換えの生きた細胞をシームレスに統合するハイブリッド・イン・シリコ／イン・セル・コントローラー（HISICC）を発表しました。これ以外にも、2023年11月、ADMとソルーゲンは戦略的パートナーシップを結び、既存の化石燃料ベースの材料に代わる分子を開発し、低炭素有機酸の製品ラインを拡大するため、約50万ft2のバイオ製造施設を建設しました。例えば、英国は、パラセタモール生産用のスケーラブルな連続フローリアクターなど、バイオリアクターの革新と生体触媒プロセスに重点を置いた、持続可能なバイオ製造業を推進するための21のセクター横断的協力に約1,400万米ドルを投資しました。これらのイニシアチブは、バイオテクノロジー・プロセスの持続可能性プロファイルを強化し、2050年までにネット・ゼロを達成するという英国の目標を支援することを目的としています。さらに、バイオリアクターメーカーは、より効率的な混合・曝気システムなど、バイオリアクター設計におけるいくつかのイノベーションに投資しており、環境に優しいバイオプロセシング・ソリューションの人気を高めています。例えば、ベーリンガーインゲルハイムは、環境の持続可能性に重点を置き、動物用医薬品におけるバイオプロセス技術を提供しています。これに伴い、抗原生物学的製剤製造のためのプロセスチェーンの最適化から、現行の慣行に関する継続的な議論と評価に至るまで、同社は環境フットプリントの最小化に強くコミットしています。さらに、2024年3月、英国研究革新庁（UKRI）は、国内全域で持続可能なバイオ製造の進歩を推進するための21の分野横断的共同研究を発表しました。

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 市場内訳：国別

第11章 SWOT分析

概要
強み
弱み
機会
脅威

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第14章価格分析

第15章競合情勢

市場構造
主要企業
主要企業のプロファイル
- 2mag AG
- bbi-biotech GmbH
- Bioengineering AG
- Eppendorf SE
- Getinge AB
- Infors AG
- Merck KGaA
- Pall Corporation（Danaher Corporation）
- Sartorius AG
- Solaris Biotechnology Srl
- Thermo Fisher Scientific Inc.

図表

List of Figures

Figure 1: Global: Bioreactors Market: Major Drivers and Challenges
Figure 2: Global: Bioreactors Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Bioreactors Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Bioreactors Market: Breakup by Type (in %), 2024
Figure 5: Global: Bioreactors Market: Breakup by Usage (in %), 2024
Figure 6: Global: Bioreactors Market: Breakup by Scale (in %), 2024
Figure 7: Global: Bioreactors Market: Breakup by Control Type (in %), 2024
Figure 8: Global: Bioreactors Market: Breakup by Region (in %), 2024
Figure 9: Global: Bioreactors (Single-Use) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Bioreactors (Single-Use) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Bioreactors (Multi-Use) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Bioreactors (Multi-Use) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Bioreactors (Lab-Scale Production) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Bioreactors (Lab-Scale Production) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Bioreactors (Pilot-Scale Production) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Bioreactors (Pilot-Scale Production) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Bioreactors (Full-Scale Production) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Bioreactors (Full-Scale Production) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Bioreactors (5L-20L) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Bioreactors (5L-20L) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Bioreactors (20L-200L) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Bioreactors (20L-200L) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Bioreactors (200L-1500L) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Bioreactors (200L-1500L) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Bioreactors (Above 1500L) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Bioreactors (Above 1500L) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Bioreactors (Manual) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Bioreactors (Manual) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: Bioreactors (Automated) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: Bioreactors (Automated) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: North America: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: North America: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: United States: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: United States: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Canada: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Canada: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Asia-Pacific: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Asia-Pacific: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: China: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: China: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Japan: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Japan: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: India: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: India: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: South Korea: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: South Korea: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: Australia: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: Australia: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Indonesia: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Indonesia: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: Others: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: Others: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: Europe: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: Europe: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: Germany: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: Germany: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: France: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: France: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: United Kingdom: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: United Kingdom: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Italy: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Italy: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Spain: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Spain: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Russia: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Russia: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Others: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Others: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Latin America: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Latin America: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Brazil: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Brazil: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Mexico: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: Mexico: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: Others: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: Others: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Middle East and Africa: Bioreactors Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: Middle East and Africa: Bioreactors Market: Breakup by Country (in %), 2024
Figure 79: Middle East and Africa: Bioreactors Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 80: Global: Bioreactors Industry: SWOT Analysis
Figure 81: Global: Bioreactors Industry: Value Chain Analysis
Figure 82: Global: Bioreactors Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Bioreactors Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Bioreactors Market Forecast: Breakup by Type (in Million USD), 2025-2033
Table 3: Global: Bioreactors Market Forecast: Breakup by Usage (in Million USD), 2025-2033
Table 4: Global: Bioreactors Market Forecast: Breakup by Scale (in Million USD), 2025-2033
Table 5: Global: Bioreactors Market Forecast: Breakup by Control Type (in Million USD), 2025-2033
Table 6: Global: Bioreactors Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Bioreactors Market: Competitive Structure
Table 8: Global: Bioreactors Market: Key Players

Product Code: SR112025A5500

The global bioreactors market size was valued at USD 8.0 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 19.6 Billion by 2033, exhibiting a CAGR of 10.4% during 2025-2033. North America currently dominates the market, holding a significant market share of over 39.1% in 2024. The increasing adoption of effective treatment drugs, along with the rising need for preventive vaccines, is primarily propelling the bioreactors market share.

The global bioreactors market is experiencing growth due to the rising demand for biologics, including monoclonal antibodies and vaccines. This can be attributed to the advancements in biopharmaceutical production. Along with this, the increasing adoption of single-use bioreactors, known for reduced contamination risks and operational costs, is further accelerating market growth. Rapid advancements in cell and gene therapy research, and growing interest in personalized medicine, are also propelling demand. Apart from this, government support for biologics manufacturing and favorable regulations for biosimilar production are contributing to the market's expansion. Moreover, technological improvements in automation and control systems are enhancing bioreactor performance, addressing the needs of the biotechnology and pharmaceutical industries, and fueling the market.

The United States stands out as a key market, driven by the growing focus on biosimilar production. This can be supported by the patent expirations of major biologics and the increasing affordability of these alternatives. In addition, the increasing prevalence of chronic diseases is encouraging biopharmaceutical investments, fueling the need for scalable and efficient bioreactor systems. As per 2024 research report by the CDC, in the United States, 129 million individuals have at least one major chronic disease defined by the US Department of Health and Human Services, such as heart disease, cancer, diabetes, obesity, or hypertension, with 42% having two or more and 12% having at least five. Chronic diseases account for five of the top 10 leading causes of death. Their prevalence has steadily increased over two decades and is expected to rise further. Besides this, expansion in bioprocessing applications, such as stem cell research and tissue engineering, is creating significant demand for specialized bioreactors. Concurrently, collaborations between academic institutions and biotech companies are accelerating advancements in biomanufacturing techniques. Furthermore, the increasing role of bioreactors in food and agricultural biotechnology is creating a positive bioreactors market outlook.

Bioreactors Market Trends:

Usage of Single-Use Bioreactors

Single-use bioreactors (SUBs) are gaining extensive popularity, owing to their benefits, such as flexibility, cost-effectiveness, reduced risk of contamination, etc. This, in turn, is stimulating the market. According to the IMARC, the global single-use bioreactors market size reached USD 3.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 11.1 Billion by 2032, thereby exhibiting a growth rate (CAGR) of 13.8% during 2024-2032. Moreover, unlike traditional stainless-steel bioreactors, SUBs adopt disposable bags, which aids in eliminating the need for extensive cleaning and sterilization between batches. In December 2023, Cellexus introduced airlift single-use disposable bioreactor systems that offer optimal aeration for the rapid growth of cells. This method of gentle agitation is usually suitable for microbial fermentation and cell culture. Besides this, key players are also producing innovative SUB designs, catering to both small-scale research and large-scale production needs, which is fueling the bioreactors market outlook. For instance, in February 2024, the contract development and manufacturing organization (CDMO), WuXi Biologics, announced the construction of a single-use site with approximately 54,000 L of disposable bioreactor capacity via an investment of roughly approximately USD 340 Million in Ireland. Additionally, in March 2024, Thermo Fisher Scientific(TM) launched a series of application-specific enhancements to the HyPerforma(TM) single-use bioreactor (SUB) product platform, each tailored to the unique requirements of intensified fed-batch, perfusion, and adherent cell cultures. Similarly, in March 2024, Distek, Inc. unveiled a single-use bioreactor (SUB) system for mammalian cell growth and recombinant protein production. Furthermore, continuous collaborations among prominent companies are projected to augment the market in the coming years. For example, in June 2024, Aragen Bioscience and Getinge announced the successful validation of the latter's single-use production reactors (SUPR). In line with this, the collaboration combined Getinge's innovative single-use technology and Aragen's expertise in biopharmaceutical manufacturing.

Advancements in Automation

On of the significant bioreactors market trends is continual advancements in automation. The widespread integration of novel control systems and automation with bioreactors is revolutionizing bioprocessing by enabling precise control over critical parameters, such as pH, temperature, dissolved oxygen, etc., and real-time monitoring. This is acting as a significant growth-inducing factor. For instance, in August 2023, Repligen Corporation and Sartorius introduced an integrated bioreactor system that comprises a fully compatible embedded XCell ATF software and hardware module offering predefined advanced control recipes with integrated process analytical technology (PAT). According to Gartner, by 2026, 30% of enterprises will automate over half of network activities, up from 10% in 2023, as AI-driven automation, including GenAI, boosts operational efficiency and agility. These advancements are increasingly applied in bioreactors, enhancing data-driven decision-making and process optimization. Additionally, the system aims to provide users with a streamlined way to control cell growth and enhance cell retention in perfusion processes without utilizing a separate cell retention control tower. Besides this, in September 2023, Automated Control Concepts (ACC), one of the innovators in biotechnology solutions, released its cutting-edge bioreactor control and data platform, Lab Owl, that allows for adjustment of multiple process parameters and precise monitoring, resulting in consistent and reproducible outcomes. Apart from this, in December 2023, Cultzyme launched a bioreactor intelligent operative nanotechnology (BION) system equipped with AI, hardware, and cloud computing to control the biomanufacturing process and achieve consistent outcomes more efficiently and at minimal costs. Furthermore, the escalating demand for advanced control systems, as they facilitate seamless scale-up from laboratory to production scale, which aids in ensuring consistent performance across numerous bioreactor sizes, is also increasing the bioreactors market revenue. For instance, in April 2024, Culture Biosciences created bioreactors with advanced control systems and real-time monitoring capabilities designed to accommodate Chinese Hamster Ovary (CHO) cells.

Development of Sustainable Bioprocessing

Sustainability is becoming a critical consideration in the market. Prominent players are focusing on minimizing energy consumption and waste generation, which is stimulating the bioreactors market growth. In October 2023, a team of researchers at the Nara Institute of Science and Technology and Fujita University introduced a hybrid in silico/in-cell controller (HISICC) that seamlessly integrates computerized feedforward control with genetically modified living cells, offering the potential for cost-effective and eco-friendly chemical and fuel production. Besides this, in November 2023, ADM and Solugen formed a strategic partnership to build an approximately 500,000-ft2 biomanufacturing facility to develop molecules to replace existing fossil fuel-based materials and scale its line of lower-carbon organic acids. For instance, the UK has invested approximately USD 14 Million in 21 cross-sector collaborations to advance sustainable biomanufacturing, focusing on bioreactor innovations and biocatalytic processes, such as scalable continuous flow reactors for paracetamol production. These initiatives aim to enhance the sustainability profile of biotechnology processes and support the UK's goal of achieving Net Zero by 2050. Moreover, bioreactor manufacturers are investing in several innovations in bioreactor design, such as more efficient mixing and aeration systems, which is elevating the popularity of greener bioprocessing solutions. For example, Boehringer Ingelheim offers bioprocess technology operations in animal health with an improved focus on environmental sustainability. In line with this, from continuously discussing and evaluating current practices to optimizing process chains for antigenic biological manufacturing, the company is strongly committed to minimizing its environmental footprint. Additionally, in March 2024, the UK Research and Innovation (UKRI) announced 21 cross-sector collaborations to drive advancements in sustainable biomanufacturing across the country.

Bioreactors Industry Segmentation:

Analysis by Type:

Single-Use
Multi-Use

Multi-use stands as the largest component in 2024, holding around 65.9% of the market. Multi-use bioreactors are the most versatile, cost-effective, and efficient bioreactors for diverse bioproduction processes. They are used in a wide range of pharmaceutical, biotechnology, and research applications because they can accommodate various cell culture and fermentation processes. Their design is robust, reusable, and scalable, making them ideal for large-scale manufacturing and experimental applications. Multi-use bioreactors are in line with the industry's demand for high-quality production and sustainable practices, as they reduce operational costs and ensure consistent performance. Their adaptability to advanced technologies further reinforces their position as the largest and most impactful segment in the bioreactors market.

Analysis by Usage:

Lab-Scale Production
Pilot-Scale Production
Full-Scale Production

Pilot-scale production leads the market with around 49.1% of market share in 2024. Pilot-scale production in bioreactors serves as a crucial intermediary step between laboratory research and full-scale manufacturing in the biopharmaceutical industry. This phase allows for the optimization of bioprocesses on a scale that closely mimics commercial production, providing valuable insights into process performance, scalability, and reproducibility. Pilot-scale bioreactors typically range from 50 to 500 liters in capacity. For instance, in January 2024, San Francisco-based SciFi Foods announced the successful completion of its first commercial bioreactor facility in San Leandro, California. They are used to test and refine production parameters such as cell growth, nutrient consumption, and product yield under conditions that replicate those of large-scale operations. Additionally, pilot-scale production facilitates regulatory compliance by generating data required for process validation and quality assurance. Companies like GE Healthcare and Sartorius offer advanced pilot-scale bioreactor systems equipped with sophisticated monitoring and control technologies, enabling precise control over critical process parameters and ensuring a seamless transition to large-scale manufacturing.

Analysis by Scale:

5L-20L
20L-200L
200L-1500L
Above 1500L

200L-1500L leads the market with around 47.8% of market share in 2024. Bioreactors are designed in various scales to meet the needs of different stages of bioprocessing, from research and development to full-scale commercial production. Bioreactors in the 200L to 1500L range are used for pilot-scale production, providing a realistic simulation of commercial-scale operations and facilitating the validation of production processes. These bioreactors hold significant prominence in the biopharmaceutical sector due to their versatility and scalability. These systems bridge the gap between laboratory-scale research and large-scale manufacturing, enabling efficient process optimization and technology transfer. Their adoption is driven by the rising demand for biologics, including monoclonal antibodies and vaccines, which require consistent and reproducible production environments.

Analysis by Control Type:

Manual
Automated

Automated leads the market with around 65.9% of market share in 2024. Automated bioreactors are revolutionizing bioprocessing by integrating advanced control systems that enhance precision, efficiency, and scalability. They allow for real-time monitoring and control of critical parameters, including temperature, pH, dissolved oxygen, etc. The system's automation capabilities minimize human intervention, thereby reducing the risk of contamination and errors while optimizing cell growth and product yield. For example, in May 2024, a team of researchers at Florida International University developed an automated 3D-printed bioreactor to grow bone in the lab. Additionally, biopharmaceutical manufacturers offer versatile and robust solutions to enhance productivity and maintain high standards of quality and compliance. For instance, in September 2023, Automated Control Concepts (ACC), one of the leading innovators in biotechnology solutions, announced the development of its cutting-edge bioreactor control and data platform, Lab Owl, to redefine the landscape of bioprocessing.

Regional Analysis:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

In 2024, North America accounted for the largest market share of over 39.1%. The North America bioreactors market is witnessing robust growth, fueled by the region's strong emphasis on biopharmaceutical research, development, and manufacturing. Additionally, advancements in bioprocessing technologies, such as single-use bioreactors and automation, are enhancing the efficiency and scalability of biomanufacturing processes. The presence of major pharmaceutical and biotechnology companies, coupled with supportive government initiatives and funding, is further propelling the bioreactors market demand. In February 2024, Thermo Fisher Scientific expanded its manufacturing capacity at its Missouri, U.S. site to produce complex biologic treatments for a range of diseases, including cancer, autoimmune conditions, and rare disorders. Furthermore, the North America bioreactors market is poised for continued growth, driven by technological advancements and increasing biopharmaceutical production demands. For instance, in March 2023, Micro Digital Co. signed a formal contract to supply bioreactors to expand its presence in North America.

Key Regional Takeaways:

United States Bioreactors Market Analysis

In 2024, US accounted for around 87.6% of the total North America bioreactors market. The United States is at the forefront of adopting bioreactor technology, significantly advancing its position in biotechnology and pharmaceutical manufacturing. Bioreactors are streamlining the production of biologics, including vaccines, monoclonal antibodies, and regenerative medicine solutions, addressing both domestic and global healthcare needs. Key advantages include higher production efficiency, scalability, and enhanced process control, enabling faster responses to medical demands. Innovations such as single-use bioreactors are reducing costs and contamination risks while supporting sustainability goals. For instance, The United States, as the world's third-largest importer of bioreactors with 191 shipments, primarily sources from Mexico, India, and Canada. This strategic importation supports advancements in biotechnology and pharmaceuticals, bolstering the nation's innovation and economic growth. Major states like California, Massachusetts, and North Carolina, with robust biotechnology clusters, are hubs for bioreactor deployment, fostering collaborations and driving R&D. These advancements are further strengthening the U.S. position as a leader in life sciences, with companies and research centers contributing to breakthroughs in personalized medicine and cell-based therapies. Bioreactors are transforming industries beyond healthcare, including biofuels and agriculture, enhancing resource management and sustainability efforts across diverse sectors.

Asia Pacific Bioreactors Market Analysis

The Asia-Pacific region is emerging as a significant hub for bioreactor adoption, driven by advancements in biotechnology and the region's focus on pharmaceutical and biopharmaceutical development. Countries such as China, India, Japan, and South Korea are leveraging bioreactor technologies to enhance vaccine production, biologics manufacturing, and regenerative medicine. These innovations are enabling cost-effective and scalable production processes, crucial for meeting the demands of growing healthcare markets. For instance, India imported 2,480 bioreactor shipments from March 2023 to February 2024, primarily from the United States, Switzerland, and Germany. This significant import activity underscores India's commitment to advancing its biotechnology sector, enhancing research capabilities, and fostering economic growth. The region's favorable regulatory frameworks and substantial investments in research hubs, particularly in cities like Shanghai, Hyderabad, and Tokyo, are positioning Asia-Pacific as a leader in bioprocessing. The adoption of single-use bioreactors in South Korea's biopharmaceutical industry and China's focus on monoclonal antibody production exemplify the region's dynamic advancements. With strategic location advantages, including proximity to raw materials and skilled labor, Asia-Pacific is fostering sustainable biotechnology growth, meeting global supply demands, and addressing critical healthcare challenges.

Europe Bioreactors Market Analysis

The adoption of bioreactors in Europe is significantly transforming industries like pharmaceuticals and biotechnology by advancing production efficiency and sustainability. Bioreactors enable precise environmental control, enhancing the yield of biologics and biofuels while reducing waste and resource consumption. Europe, particularly Germany and Switzerland, leads in bioreactor innovation, leveraging advancements in automation and sensor technologies to optimize processes. Germany's pharmaceutical hubs utilize bioreactors to streamline vaccine production, meeting global health demands rapidly. Similarly, Switzerland's biotechnology sector has integrated bioreactors to enhance monoclonal antibody manufacturing, positioning the country as a leader in therapeutic advancements. Switzerland's export of bioreactors and effluent treatment equipment significantly benefits Europe by enhancing wastewater management and environmental sustainability. In 2024, Switzerland exported 2,474 shipments of MBR bioreactor treatment plant sections and related equipment, indicating robust trade activity in this sector. The widespread adoption across European countries, including the Netherlands and France, emphasizes the region's commitment to green technology and reduced carbon footprints. By fostering innovation hubs and research centers, Europe strengthens its position in global biotechnology, offering scalable solutions that address industrial and environmental challenges while maintaining a competitive edge in life sciences.

Latin America Bioreactors Market Analysis

The adoption of bioreactors in Latin America is revolutionizing biotechnology and sustainable production. Advancements in scalable cell culture and fermentation technologies enable efficient vaccine development and bio-based manufacturing. Countries like Brazil are leveraging bioreactors for ethanol production from sugarcane, enhancing renewable energy output. Similarly, Mexico utilizes bioreactors in pharmaceutical innovation, improving drug manufacturing. According to reports, The Mexico small-scale bioreactors market is projected to grow from USD 36.9 Million in 2018 to USD 154.1 Million by 2032, driven by increasing adoption in medical, food, agriculture, and energy sectors. These innovations position Latin America as a global hub for biotechnological progress. Strategically located near global trade routes, the region fosters economic growth through exports. States such as Sao Paulo and Jalisco exemplify leadership, driving technological adoption to support environmental sustainability and economic development.

Middle East and Africa Bioreactors Market Analysis

The Middle East and Africa are rapidly embracing bioreactors, revolutionizing biotechnology, and healthcare sectors. Bioreactors offer advantages such as enhanced cell growth, scalability, and precise environmental control, fostering innovation in pharmaceutical production and wastewater treatment. According to reports, the United Arab Emirates imported 12 bioreactor shipments, ranking 22nd globally. India led with 2,480 shipments, followed by Vietnam with 225, and the United States with 209. Advancements in single-use bioreactors and automation have streamlined operations, making them accessible to emerging markets. For instance, Saudi Arabia is utilizing bioreactors for vaccine manufacturing, ensuring local supply chains, while South Africa is employing them in biofuel production to address energy sustainability. Strategic positioning in these regions promotes economic diversification and self-reliance, making bioreactors a pivotal tool for regional growth.

Competitive Landscape:

The bioreactors market forecast indicates strong competition in the market, as key players iare focusing on innovation to enhance efficiency and scalability in bioprocessing. They are investing in advanced technologies such as single-use systems to meet the growing demand for flexible and cost-effective solutions. Companies are also expanding their portfolios to include modular and custom bioreactors tailored to specific applications such as cell and gene therapy. Along with this, partnerships with biotech firms and research institutions are strengthening R&D efforts, fostering the development of next-generation bioreactors. Additionally, manufacturers are leveraging automation and digital monitoring tools to improve process control and product quality.

The report provides a comprehensive analysis of the competitive landscape in the bioreactors market with detailed profiles of all major companies, including:

2mag AG
bbi-biotech GmbH
Bioengineering AG
Eppendorf SE
Getinge AB
Infors AG
Merck KGaA
Pall Corporation (Danaher Corporation)
Sartorius AG
Solaris Biotechnology Srl
Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

1.How big is the bioreactors market?
2.What is the future outlook of the bioreactors market?
3.What are the key factors driving the bioreactors market?
4.Which region accounts for the largest bioreactors market share?
5.Which are the leading companies in the global bioreactors market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Bioreactors Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Single-Use
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Multi-Use
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Usage

7.1 Lab-Scale Production
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Pilot-Scale Production
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Full-Scale Production
- 7.3.1 Market Trends
- 7.3.2 Market Forecast

8 Market Breakup by Scale

8.1 5L-20L
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 20L-200L
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 200L-1500L
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Above 1500L
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Control Type

9.1 Manual
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Automated
- 9.2.1 Market Trends
- 9.2.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 2mag AG
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
- 15.3.2 bbi-biotech GmbH
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
- 15.3.3 Bioengineering AG
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
- 15.3.4 Eppendorf SE
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Getinge AB
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 Infors AG
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
- 15.3.7 Merck KGaA
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Pall Corporation (Danaher Corporation)
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
- 15.3.9 Sartorius AG
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Solaris Biotechnology Srl
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
- 15.3.11 Thermo Fisher Scientific Inc.
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis

バイオリアクターの市場規模、シェア、動向、予測：タイプ、用途、スケール、制御タイプ、地域別、2025年～2033年

Bioreactors Market Size, Share, Trends, and Forecast by Type, Usage, Scale, Control Type, and Region, 2025-2033

バイオリアクターの市場の動向：

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のバイオリアクター市場

第6章 市場内訳：タイプ別

第7章 市場内訳：用途別

第8章 市場内訳：スケール別

第9章 市場内訳：コントロールタイプ別

第10章 市場内訳：地域別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢